Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Sep 30;14(9):4175-4179.
doi: 10.21037/tlcr-2025-625. Epub 2025 Sep 25.

NY-ESO-1 targeting in non-small cell lung cancer: promise and challenges of letetresgene autoleucel

Federico Monaca  1 , Igor Gómez-Randulfe  1 , Raffaele Califano  1   2
Affiliations
Editorial

NY-ESO-1 targeting in non-small cell lung cancer: promise and challenges of letetresgene autoleucel

Federico Monaca et al. Transl Lung Cancer Res. .
No abstract available

Keywords: New York esophageal squamous cell carcinoma 1 (NY-ESO-1); Non-small cell lung cancer (NSCLC); TCR-T therapy; adoptive cell therapy; letetresgene autoleucel (lete-cel).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2025-625/coif). R.C. reports grants paid to Institution by Roche, AstraZeneca, Pfizer, Clovis, Lilly Oncology, MSD, BMS, Abbvie, Takeda, Janssen, and Novartis; and consulting fees from AstraZeneca, Boeringher Ingelheim, Lilly Oncology, Roche, Pfizer, MSD, BMS, Takeda, Janssen, Bayer, and Novartis. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Garassino MC, Gadgeel S, Speranza G, et al. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol 2023;41:1992-8. 10.1200/JCO.22.01989 - DOI - PMC - PubMed
    1. Schoenfeld AJ, Hellmann MD. Acquired Resistance to Immune Checkpoint Inhibitors. Cancer Cell 2020;37:443-55. 10.1016/j.ccell.2020.03.017 - DOI - PMC - PubMed
    1. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med 2018;378:439-48. 10.1056/NEJMoa1709866 - DOI - PMC - PubMed
    1. Yarchoan M, Johnson BA, 3rd, Lutz ER, et al. Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer 2017;17:209-22. 10.1038/nrc.2016.154 - DOI - PMC - PubMed
    1. Jungbluth AA, Chen YT, Stockert E, et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 2001;92:856-60. 10.1002/ijc.1282 - DOI - PubMed